Bangladesh
· Delayed Price · Currency is BDT IBNSINA Statistics
Total Valuation
The IBN SINA Pharmaceutical Industry has a market cap or net worth of BDT 10.81 billion. The enterprise value is 11.92 billion.
| Market Cap | 10.81B |
| Enterprise Value | 11.92B |
Important Dates
The last earnings date was Wednesday, September 11, 2024.
| Earnings Date | Sep 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
The IBN SINA Pharmaceutical Industry has 31.24 million shares outstanding.
| Shares Outstanding | 31.24M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.37% |
| Owned by Institutions (%) | 44.31% |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 15.67 and the forward PE ratio is 14.18.
| PE Ratio | 15.67 |
| Forward PE | 14.18 |
| PS Ratio | 0.99 |
| PB Ratio | 3.24 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.32, with an EV/FCF ratio of -34.99.
| EV / Earnings | 17.29 |
| EV / Sales | 1.10 |
| EV / EBITDA | 10.32 |
| EV / EBIT | 12.51 |
| EV / FCF | -34.99 |
Financial Position
The company has a current ratio of 1.07, with a Debt / Equity ratio of 47.52.
| Current Ratio | 1.07 |
| Quick Ratio | 0.28 |
| Debt / Equity | 47.52 |
| Debt / EBITDA | 1.39 |
| Debt / FCF | -4.70 |
| Interest Coverage | 19.75 |
Financial Efficiency
Return on equity (ROE) is 22.17% and return on invested capital (ROIC) is 13.60%.
| Return on Equity (ROE) | 22.17% |
| Return on Assets (ROA) | 11.16% |
| Return on Capital (ROIC) | 13.60% |
| Revenue Per Employee | 2.72M |
| Profits Per Employee | 172,449 |
| Employee Count | 4,000 |
| Asset Turnover | 2.04 |
| Inventory Turnover | 5.18 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +20.73% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +20.73% |
| 50-Day Moving Average | 283.61 |
| 200-Day Moving Average | 271.29 |
| Relative Strength Index (RSI) | 65.80 |
| Average Volume (20 Days) | 294,540 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, The IBN SINA Pharmaceutical Industry had revenue of BDT 10.87 billion and earned 689.80 million in profits. Earnings per share was 22.08.
| Revenue | 10.87B |
| Gross Profit | 4.45B |
| Operating Income | 952.91M |
| Pretax Income | 926.73M |
| Net Income | 689.80M |
| EBITDA | 1.13B |
| EBIT | 952.91M |
| Earnings Per Share (EPS) | 22.08 |
Balance Sheet
The company has 495.93 million in cash and 1.60 billion in debt, giving a net cash position of -1.08 billion or -34.53 per share.
| Cash & Cash Equivalents | 495.93M |
| Total Debt | 1.60B |
| Net Cash | -1.08B |
| Net Cash Per Share | -34.53 |
| Equity (Book Value) | 3.37B |
| Book Value Per Share | 106.75 |
| Working Capital | 152.90M |
Cash Flow
In the last 12 months, operating cash flow was 815.53 million and capital expenditures -1.16 billion, giving a free cash flow of -340.79 million.
| Operating Cash Flow | 815.53M |
| Capital Expenditures | -1.16B |
| Free Cash Flow | -340.79M |
| FCF Per Share | -10.91 |
Margins
Gross margin is 40.96%, with operating and profit margins of 8.77% and 6.35%.
| Gross Margin | 40.96% |
| Operating Margin | 8.77% |
| Pretax Margin | 8.53% |
| Profit Margin | 6.35% |
| EBITDA Margin | 10.40% |
| EBIT Margin | 8.77% |
| FCF Margin | -3.14% |
Dividends & Yields
This stock pays an annual dividend of 6.00, which amounts to a dividend yield of 1.73%.
| Dividend Per Share | 6.00 |
| Dividend Yield | 1.73% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 22.44% |
| Buyback Yield | n/a |
| Shareholder Yield | 1.73% |
| Earnings Yield | 6.38% |
| FCF Yield | -3.15% |
Stock Splits
The last stock split was on October 23, 2018. It was a forward split with a ratio of 1.1.
| Last Split Date | Oct 23, 2018 |
| Split Type | Forward |
| Split Ratio | 1.1 |